United States Patent 6,429,230: Scope of Claims and U.S. Patent Landscape for Carnitine Supplementation in Chronic Uremic Dialysis

US 6,429,230 is a method patent focused on preventing or treating carnitine deficiency in chronic uremic patients receiving periodic dialysis by administering L-carnitine (or pharmaceutically acceptable salts) directly into a dialysis venous return line after a dialysis session, with defined dosing windows, repetition intervals, optional maintenance dosing, and patient selection thresholds based on pre-dialysis plasma carnitine concentrations.

What is the core claim scope in US 6,429,230?

The claims share a common treatment architecture:

Indication/target population: “chronic uremic patients undergoing periodic dialysis”
Condition: “carnitine deficiency”
Route/timing: administration into a venous return line after a dialysis session (Claims 1, 9-11, 16) and, in at least one claim, at the conclusion of dialysis (Claim 15)
Drug form: L-carnitine or pharmaceutically acceptable salt, with carnitine fumarate explicitly claimed (Claim 6)
Dose magnitude (induction): 10 to 20 mg/kg body weight of L-carnitine (Claims 1, 9-10, 16)
Dose schedule (induction/continuation): repeated twice a week every 44 hours, then after 68 hours (Claims 1, 5, 11)
Optional treatment duration: 3-4 weeks (Claims 2, 12)
Patient stratification/threshold: pre-dialysis plasma carnitine ≤ 40-50 μM (Claims 3, 13, 15, 16)
Maintenance strategy: reduce dose after restoring to at least pre-dialytic level, including a specific maintenance dose of ~5 mg/kg (Claims 4-5, 9-10, 14)

Claim-independent “anchor” concepts

Because most claims depend on Claim 1 or Claim 9, the enforceable center of gravity is the combination of:

1) dialysis-timed infusion into the venous return line,
2) L-carnitine dosing at 10 to 20 mg/kg,
3) repetition intervals tied to “twice a week every 44 hours, then after 68 hours,” and
4) optionally selecting/continuing therapy based on a 40-50 μM pre-dialysis carnitine threshold, and/or using a maintenance reduction approach anchored to restoring and maintaining pre-dialytic levels.

What does each claim add to enforceability?

Claims 1-3: induction dose and schedule with carnitine threshold

Claim 1 (independent): Method of preventing or treating carnitine deficiency in chronic uremic dialysis patients by administering into the venous return line after a dialysis session:
- 10 to 20 mg/kg L-carnitine (or salt)
- then repeat twice a week every 44 hours, then after 68 hours
Claim 2: continues for 3-4 weeks, monitoring pre-dialytic levels
Claim 3: pre-dialytic levels ≤ 40-50 μM

Enforcement consequence: A generic carnitine strategy that uses the same route and dose range but does not follow the specific repetition intervals may avoid coverage of Claim 1. A strategy that uses different route (oral, subcutaneous, separate IV line) may also avoid literal scope.

Claims 4-6: maintenance dosing and specific salt

Claim 4: maintenance dosage 5 mg/kg carnitine
Claim 5: maintenance repeats on twice a week every 44 hours, then after 68 hours
Claim 6: salt is carnitine fumarate

Enforcement consequence: The patent distinguishes induction (10-20 mg/kg) from maintenance (about 5 mg/kg). If a competitor maintains by a different dose level or schedule, it may avoid Claims 4-5. If a competitor uses a different salt form, Claim 6 may be avoided, but other salts remain potentially covered under “pharmaceutically acceptable salt thereof” in broader dependent claims.

Claims 7-8: comorbidity limitations (hypervolemic heart, diabetes)

Claim 7: patient has “hypervolemic heart”
Claim 8: patient has diabetes

Enforcement consequence: These claims narrow the population further. A method performed on patients without those conditions does not fall within those specific claims.

Claims 9-14: restore-to-pre-dialytic-level concept and maintenance reduction

Claim 9 (independent): administer into venous return line after dialysis session:
- an amount effective to restore carnitine level to at least the pre-dialytic level
- thereafter reduce administered amount to maintain at the pre-dialytic level
Claim 10 (independent): same as Claim 9 but explicitly uses 10 to 20 mg/kg (calculated as L-carnitine)
Claim 11: induction/weekly basis repeated twice a week every 44 hours, then after 68 hours
Claim 12: treatment to achieve pre-dialytic levels continued for 3-4 weeks
Claim 13: pre-dialytic levels ≤ 40-50 μM
Claim 14: maintenance dosage about 5 mg/kg

Enforcement consequence: Claims 9 and 10 broaden the mechanistic framing. They can potentially capture regimens that vary the exact induction scheduling as long as the method includes:

venous return-line post-dialysis administration, and
titration logic: restore to pre-dialytic levels, then reduce to maintain those levels,
with dose and schedule added in dependent claims.

Claims 15-16: diagnostic prompting and monitoring-based control

Claim 15: administer at conclusion of dialysis only when prompted by demonstration of an initial pre-dialysis plasma carnitine level ≤ 40-50 μM
Claim 16: administer into venous return line after dialysis session 10 to 20 mg/kg, and repeat while monitoring pre-dialysis plasma carnitine levels

Enforcement consequence: Claim 15 is built around conditional use based on a specific baseline diagnostic threshold. Claim 16 incorporates a monitoring step during repeat administrations, which can be relevant in disputes if a competitor does not monitor or does not use threshold-based clinical decisioning.

Scope in plain dosing and workflow terms

The patent is operationally tied to a dialysis day workflow:

1) Measure pre-dialysis plasma carnitine and identify patients at ≤ 40-50 μM (for certain dependent claims; also used as a prompt in Claim 15). 2) After a dialysis session, infuse L-carnitine (10-20 mg/kg) into the venous return line. 3) Repeat administration twice weekly with the specific temporal pattern “every 44 hours, then after 68 hours.” 4) Optionally continue for 3-4 weeks to reach pre-dialytic target levels. 5) Optionally switch to maintenance at ~5 mg/kg, repeated on the same schedule. 6) Optionally use a specific salt like carnitine fumarate.

What is the patent landscape impact in the U.S.?

US 6,429,230 is a method-of-treatment patent with narrow technical hooks: dialysis-timed administration into the venous return line, specific mg/kg ranges, and the cadence tied to “44 hours then after 68 hours,” plus a plasma carnitine threshold (40-50 μM) and a titration-to-pre-dialytic-level maintenance concept.

Competitive design-around levers

A competitor seeking to avoid literal coverage typically targets at least one element of the method:

Route: avoid venous return line administration (e.g., administer elsewhere during/after dialysis through a different access route).
Dose range: use doses outside 10-20 mg/kg for the induction phase.
Schedule: avoid “twice a week every 44 hours, then after 68 hours.”
Selection criteria: do not use the ≤40-50 μM pre-dialysis threshold as a decision trigger (or avoid baseline threshold monitoring in the same way).
Salt form: use a different pharmaceutically acceptable salt where the specific “carnitine fumarate” limitation is relevant.
Titration logic: do not frame maintenance as reduction to keep carnitine at “pre-dialytic level” (though this is harder to avoid because “maintenance” regimens are often inherently framed relative to baseline).

Business impact considerations

If a company plans a carnitine product or protocol for dialysis patients, this patent defines a clear “do-not-step-into” territory: post-dialysis venous return-line L-carnitine at 10-20 mg/kg with the defined cadence and monitoring/threshold elements.
If a company’s protocol matches the dose range and dialysis post-timing but uses different access route or schedule, the risk concentrates in whether dependent claims (monitoring, threshold prompt, maintenance dose, fumarate) can still be met.

Claim chart style map (key limitations vs. competitor protocol parameters)

Limitation cluster in US 6,429,230	Appears in claims	Protocol elements that must align for infringement risk
Chronic uremic dialysis patients with carnitine deficiency	1, 9, 10, 15-16	Indication and patient population
Administration into venous return line after dialysis session	1, 9-11, 16	Route and timing on dialysis day
L-carnitine dose 10-20 mg/kg	1, 10, 16 (and related dependent)	Induction dose magnitude
“twice a week every 44 hours, then after 68 hours” cadence	1, 5, 11	Specific repeat interval
Maintain by restoring to at least pre-dialytic level then reducing	9-10	Titration-to-baseline logic
Maintenance dose ~5 mg/kg	4, 5, 14	Exact maintenance dose
Pre-dialytic plasma carnitine threshold ≤40-50 μM	3, 13, 15-16	Diagnostic trigger and/or monitoring step
Salt: carnitine fumarate	6	Salt identity

How broad is the protection?

The patent is not broad across all carnitine supplementation in renal disease. It is tightly anchored to:

dialysis context (periodic dialysis),
a specific route (venous return line),
a specific drug (L-carnitine and salts),
defined dosing windows and schedules for key dependent claims,
and clinically actionable monitoring thresholds (≤40-50 μM).

That structure tends to make the patent most relevant for hospital/clinic-administered regimens that use dialysis access for drug infusion and that track plasma carnitine levels to guide dosing.

Key takeaways for landscape and strategy

Most valuable enforceable “core” elements: venous return-line administration after dialysis plus an induction dose range of 10-20 mg/kg, with a characteristic repeat cadence in key dependent claims.
Secondary enforceable elements: the ≤40-50 μM pre-dialysis carnitine threshold and a maintenance concept of reducing dosing to maintain pre-dialytic levels, including a specific ~5 mg/kg maintenance dose.
Salt-specific coverage exists: carnitine fumarate is explicitly claimed; other salts remain covered under generic “pharmaceutically acceptable salt,” but the fumarate-dependent claim adds a stronger anchor for that specific salt form.
Design-around is method-sensitive: route, schedule, and diagnostic trigger choices materially affect whether a protocol reads on the claims.

FAQs

1) What is the main claim that captures the treatment protocol?

Claims 1 and 9 are the principal anchors: Claim 1 specifies 10-20 mg/kg into the venous return line after dialysis with the defined “44 hours then 68 hours” cadence; Claim 9 defines a titration approach to restore at least pre-dialytic levels and then reduce to maintain them.

2) Does the patent cover oral or non-dialysis-route carnitine use?

The claims repeatedly require administration into a venous return line after a dialysis session (and, for one claim, “at the conclusion of the dialysis” with a threshold trigger). Those requirements are route- and timing-specific, so the scope is centered on dialysis-day administration through dialysis access.

3) What pre-dialysis carnitine level matters?

Multiple claims use a threshold of equal or lower than 40-50 μM pre-dialytic plasma carnitine, either as a dependent limitation or as a diagnostic “prompt” for initiating administration.

4) What maintenance regimen is claimed?

Maintenance is claimed as about 5 mg/kg carnitine (Claims 4 and 14), and it can be repeated with the same cadence as the induction regimen (Claim 5). Claim 9 frames maintenance as dose reduction to maintain carnitine at the pre-dialytic level.

5) Is “carnitine fumarate” explicitly covered?

Yes. Claim 6 limits a dependent salt to carnitine fumarate.

References

United States Patent 6,429,230. (Issued date not provided in prompt). “Method of preventing or treating carnitine deficiency in chronic uremic patients undergoing periodic dialysis.”

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	3050201	⤷ Start Trial
Canada	2381187	⤷ Start Trial
European Patent Office	1257266	⤷ Start Trial
World Intellectual Property Organization (WIPO)	0152836	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,429,230

Summary for Patent: 6,429,230